All News
Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato
Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH
Encouraging data for JAKs in this disease; need proper trials
#ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip
Mike Putman EBRheum ( View Tweet)
On now: The Great Debate - is MCTD a distinct clinical entity?
@DrLisaCS reviews the history of MCTD classification criteria and its evolution
Kasukawa criteria may be most sensitive in one cohort
@RheumNow #ACR24 https://t.co/rDHafZVL1I
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (neutrophil degranulation, ECM, tissue remodeling) involved in lupus nephritis Class II.
@RheumNow #ACR24 https://t.co/kufd2zl9yc
Akhil Sood MD AkhilSoodMD ( View Tweet)
Is there a less invasive approach to evaluate lupus nephritis?
Abstract 1683 highlights the potential role of 68Ga-FAPI PET imaging in evaluating for lupus nephritis. FAPI uptake ↑ in pts with lupus nephritis vs HC. Correlated with IFN -α and IFN-γ pathways.
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Will my patient with lupus nephritis respond well to induction therapy?
Abstract 1685: Aundhia et al demonstrate the promising utility of RAIL to predict complete renal response in patients with lupus nephritis (Class III or IV +/- V)
@RheumNow #ACR24 https://t.co/JBldrrwUhN
Akhil Sood MD AkhilSoodMD ( View Tweet)
Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE
Belimumab ~ 600% increase!!
@RheumNow #ACR24 abst#1259 https://t.co/norl1xk2KF
Bella Mehta bella_mehta ( View Tweet)
#SLE treatments #ACR24:
Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (BLyS) and proliferation-inducing ligand(APRIL))
Both improved disease activity with no difference in efficacy
Belimumab had lower infection rates
@RheumNow abst1544
Bella Mehta bella_mehta ( View Tweet)
More data from PAISLEY, deucravacitinib in SLE
Small but significant benefit w/respect to joints, a little disappointing tbh
Would like to see this for all manifestations ie pericarditis, pleuritis, etc
Anyone have an infographic or useful chart?
#ACR20 @RheumNow Abstr#1552 https://t.co/tXUoUtssxo
Mike Putman EBRheum ( View Tweet)
Low uptake of SGLT2i in Lupus nephritis
SGLT2i users had similar adverse event rates as ACEi/ARB users
SGLT2i users experienced more weight loss
#ACR24 @rheumnow abst#1534 https://t.co/tB5o7tyhu5
Bella Mehta bella_mehta ( View Tweet)
Study on SLE and NMO overlap:
Higher risk of acute cystitis & severe sepsis in hospitalized patients
SLE/NMO overlap patients 3x more likely to develop acute cystitis
2x more likely to develop severe sepsis #ACR24 @RheumNow abst#1529
Bella Mehta bella_mehta ( View Tweet)
Study on SLE treatments:
Compared adverse events of anifrolumab vs. belimumab
Similar risks for mortality, sepsis, herpes zoster, dialysis, MACE, PE/VTE, COVID-19, URI, pneumonia, and mental illness #ACR24 @RheumNow abst#1527
Bella Mehta bella_mehta ( View Tweet)
Study on severe lymphopenia in SLE:
- Assessed incidence, risk factors, and outcomes
- 11.52% of SLE patients experienced severe lymphopenia
- Higher infection rates during severe lymphopenia period
= No opportunistic infections observed #ACR24 abst#1519 @rheumnow @HSSProfEd
Bella Mehta bella_mehta ( View Tweet)
Study on pregnancy outcomes in SLE with thrombocytopenia:
Higher disease activity, pregnancy loss, and stillbirth rates
Identified risk factors: Anti-β2GP-I positivity and higher SLEDAI score #ACR24 abst#1487 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Study on cardiovascular deaths in SLE:
- Analyzed 1999-2020 data
- Overall decline in mortality rates, but recent increase since 2014
- Higher rates in women and African Americans
- Geographic disparities noted
#ACR24 abst#0998 @rheumnow https://t.co/dpjsl0gI0x
Bella Mehta bella_mehta ( View Tweet)
How do we prevent SLE flares requiring steroids?
Petri:
Background medication!
HCQ adherence is key
-check WB levels to measure
EULAR recs early addition of immunosuppress/biols
“Taper quickly, withdraw slowly”
Come down quick, then slowly off
@RheumNow #ACR24 @jhrheumatology
Eric Dein ericdeinmd ( View Tweet)
Petri recommends IM triamcinolone as safer than prednisone dosing per FLOAT trial, decreased risk of fx
@RheumNow #ACR24
@jhrheumatology https://t.co/vhMRdSkBAA https://t.co/novlGcss6x
Eric Dein ericdeinmd ( View Tweet)
Petri recommends IM triamcinolone as safer than prednisone dosing per FLOAT trial, decreased risk of fx
@RheumNow #ACR24
@jhrheumatology https://t.co/vhMRdSkBAA https://t.co/novlGcss6x
Eric Dein ericdeinmd ( View Tweet)
How do you treat a flare of SLE with steroids?
@RheumNow #ACR24
Eric Dein ericdeinmd ( View Tweet)
Petri: 5 mg prednisone or less is our standard for lupus control
EULAR 23 recs - early addition of immunosuppressant and/or biologics instead to prevent steroids
@RheumNow
#ACR24 @jhrheumatology https://t.co/jhxEeboPu5
Eric Dein ericdeinmd ( View Tweet)
Reset the bar for remission (off steroids)!! Session #17S19
3% higher risk of organ damage for each 1mg of pred
Remission possible in rheum with lower dose GC regimen and faster taper #GCStewardship
#ACR24 @RheumNow @BethIWallace
Jiha Lee JihaRheum ( View Tweet)